[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin-lymphoma-category\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin-lymphoma-category":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100586769",false,"NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","BASTION","Inclusion Criteria:\n\n* Histologically confirmed first diagnosis of cHL\n* Advanced-stage disease: stage IIB with large mediastinal mass and\u002For extranodal lesions or stage III or IV\n* No previous treatment for HL with the exception of steroid prephase\n* Confirmed HIV infection with CD4 counts ≥ 150\u002FμL at registration or \\> 250\u002FμL at any time within 8 months prior to HL diagnosis\n* Continuation of antiretroviral treatment (ART) \u002F Initiation of ART in patients who are ART-naive\n* Age: 18-60 years\n\nExclusion Criteria:\n\n* Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Multi-drug resistant HIV infection or concurrent AIDS-defining conditions\n* Pregnancy or breastfeeding","ALL","18 Years","60 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.",[26],"Hodgkin Lymphoma (Category)",[28,29,30],"advanced stage","HIV positive","Brentuximab Vedotin","NOT_YET_RECRUITING","2025-04-02",{"date":34,"type":35},"2025-04-09","ACTUAL",{"date":37,"type":20},"2025-08",{"date":39,"type":20},"2030-01",{"name":41,"class":42},"University of Cologne","OTHER",{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100574640","NCT06761911","BV in the Treatment of Relapsed\u002Frefractory Hodgkin Lymphoma","A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.\n* Patients were treated with BV-containing regimen at least once\n* Presence of tumor (measurable or nonmeasurable).\n* Signature of the form consent for participation in the study.\n\nExclusion Criteria:\n\n* \\\u003C18 years",{"count":50,"type":20},100,[52],"PHASE4","The goal of this clinical trial is to explore the real-world Chinese relapsed\u002Frefractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:\n\nTo evaluate the efficacy and toxicity of BV-containing regimen in relapsed\u002Frefractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.",[26],[30,56,57,58,59],"Hodgkin lymphoma","refractory recurrence","real world","china","2025-01-06",{"date":62,"type":35},"2025-01-07",{"date":64,"type":20},"2024-12-31",{"date":66,"type":20},"2026-01-31",{"name":68,"class":42},"Xiuhua Sun",""]